P RODUCT S Effective range of surface disinfectants
Coronaviruses (CoVs) is an enveloped virus, which means that the virus is held within a lipid envelope. Despite the serious nature of the disease some of these enveloped viruses can cause, they are easily compromised by most disinfectants. PDI offers several surface disinfectant products with proven efficacy to European
Norm EN 14476 for enveloped viruses. The following products are effective against Coronavirus: Sani-Cloth Chlor, Sani-Cloth AF Universal, Super Sani-Cloth Plus, Sani-Cloth 70 and Sani-Cloth Active. It is important to ensure the surface remains wet for the required contact time to allow the disinfectant to work. PDI Sani- Cloth Chlor has been tested to Human Coronavirus EPA to a contact time of 1 minute, while PDI Sani-Cloth AF Universal, Sani-Cloth 70 and Super Sani-Cloth Plus are effective against enveloped viruses in just 30 seconds of contact time or less. PDI Sani-Cloth Active is effective also against enveloped viruses tested to DVV/RKI in just 30 seconds.
Device defends against airborne viruses
Novaerus air disinfection devices, from H&R HEALTHCARE, provide the first line of protection against airborne viruses and bacteria. The devices ensure efficacy, safety, ease of use and affordability, reducing the risk of nosocomial infections. Novaerus devices are powered by
Nanostrike technology. This patented, plasma-based, nanotechnology uses an atmospheric plasma discharge — the same type of discharge found in lightning strikes — to kill and deactivate harmful airborne microorganisms. Novaerus portable devices come in three configurations to suit different requirements. The Protect 200 is compact yet powerful, designed for small rooms or office environments. The Protect 800 is designed for medium sized rooms such as wards, clinics, waiting rooms and communal areas. Both devices use low energy, are low maintenance and suitable for 24/7 operation.
Novaerus’ most powerful air dis-infection
Clinical evaluation of ventilator
device, the Defend 1050, combines NanoStrike technology with a triple-stage filtration system from Camfil. This portable, safe device provides purification and particle removal within the cleanroom and infectious diseases environment. Recent independent laboratory testing has proven the Defend 1050 highly effective against MS2 Bacteriophage, a surrogate for SARS-COV-2 (COVID 19) and influenza viruses, reducing the airborne load by 99.99% in 15 minutes. Many hospitals worldwide, including in Wuhan, China, have installed the device to help reduce transmission of SARS-CoV-2 among healthcare workers and patients.
Bladder scanners and biomedical testers
DE SMIT MEDICAL, a distributor of medical devices and training, has announced the latest addition to the popular BioCon range of bladder scanners, the BioCon-1100. The model, which features a 10.1”, high quality colour touch display and is patient data password protected, is offered with an onboard tutorial and scan guide, to ensure the technology is user-friendly. It is supplied with an optional barcode reader, an integral thermal printer and WiFi capability. The company also provides a range of biomedical testers. The vPad-RF tester is accurate, easy to read and offers automatic
testing on all models of diathermy, including Medtronic, Erbe, Bowa, Olympus, Conmed and more. Testing features include: l Digital REM l Power l current to 8.5A l 600W internal resistor bank l external foot control l leakage measurement l voltage measurement l Vpeak & Vpeak-peak l crest factor
90 l
WWW.CLINICALSERVICESJOURNAL.COM OCTOBER 2020
An evaluation has been conducted to assess, audit and evaluate the use of the DRÄGER Oxylog VE300 ventilator and the attitudes of its users towards the device, during a six week trial period, with the critical care paramedics of SECAmb (South East Coast Ambulance Service NHS Foundation Trust). The Oxylog VE300 features a “CPR mode”, which was of particular interest to the CCPs for evaluation in clinical practice. Five Oxylog VE300 ventilators were provided for the project and delivered to two SECamb bases. Training was provided to each team, with identified team leaders having advanced training on the product. The advanced training team agreed default configurations of the device and protocol for its use. Pre and post use surveys were created to provide invaluable product feedback. The Oxylog VE300s were used in 55 different ventilation cases with all available ventilation modes: intra-arrest/CPR mode, post ROSC/ apnoeic patients, transport, handover and NIV/CPAP. The CPR mode was used in more than every second ventilation case. During CPR, ILCOR guidelines on ventilation are rarely achieved due to a tendency to either over or under ventilate patients. The Oxylog VE300’s inclusive ‘CPR mode’ is pre-set to deliver ILCOR recommended ventilations, as well as modulate flow during compressions in order to effectively deliver tidal volumes without excessive airway pressure. Clinicians were impressed with the device and the majority (81.8%) felt that their overall experience was positive.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
